Evidence map›Paper›PMID 39497481›Full record

ArticleHIV medicine2025

Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4-FHDH).

S Abgrall, H Selinger-Leneman, E Lanoy, A Becker, S Matheron, P de Truchis, J Pavie, A Canestri, M A Khuong, D Rey and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

S AbgrallAP-HP, Hôpital Béclère, Service de Médecine Interne, Clamart, and Université Paris-Saclay, CESP INSERM U1018, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-7891-7594
H Selinger-LenemanSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
E LanoySorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
A BeckerHospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France.
S MatheronAP-HP, Hôpital Bichat-Claude Bernard, GHU Paris Nord, Paris, France.
P de TruchisAP-HP Hôpital Raymond Poincaré, Université Paris-Saclay, Garches, France.
J PavieAP-HP, Hôtel-Dieu, Paris, France.
A CanestriAP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
M A KhuongHôpital Delafontaine, Saint-Denis, France.
D ReyStrasbourg University Hospital, Strasbourg, France.
F CabySorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
P TattevinPontchaillou University Hospital, Rennes, France.
R PalichSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
S GrabarSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital St Antoine, Paris, France.ORCID https://orcid.org/0000-0002-4816-4261
ANRS CO4‐FHDH

Funding

ANRS-MIEInstitut National de la Santé et de la Recherche MédicaleSorbonne Universitéthe French Ministry of Health
6 · The paper itself

Abstract

backgroundAssessing the potential increased risk of viral rebound (VR) in migrants requires adequate control for sex and acquisition risk groups.

methodsPeople living with HIV1, enrolled in the ANRS CO4-French Hospital Database on HIV, who achieved virological suppression with antiretroviral therapy (ART) initiated between 2006 and 2016 were included. We first compared the risk of VR, with loss to follow-up and death considered as competing events, across origin among the HIV acquisition groups, then across acquisition groups among the different origins, and finally across modality of a variable combining sex, acquisition group, and origin. Models were adjusted for clinical and biological confounding factors.

resultsWe included 21 571 French natives (FRA), 10 148 migrants from sub-Saharan Africa (SSA), 1137 migrants from the non-French West Indies (NFWI), and 4205 other migrants (OTHER). The 5-year probability of VR was 19% (95% confidence interval [CI] 19-20) overall, 15% in FRA, 21% in OTHER, 26% in SSA, and 34% in NFWI (p < 0.0001). It was 14% in men who have sex with men (MSM), 23% in heterosexual men, and 23% in women (p < 0.0001). After adjustment, all acquisition groups had a higher risk of VR than MSM from FRA, with men and women from NFWI having the highest risk (adjusted hazard ratio [aHR] 2.46; 95% CI 2.12-2.86 and aHR 2.59; 95% CI 2.20-3.04, respectively). Within each acquisition group, all groups of origin had a higher risk of VR than FRA. Within each region of origin, except the NFWI, heterosexual men had a higher risk of VR than MSM.

conclusionsAfter accounting for sex and acquisition group, migration, especially from NFWI, remains prognostic of VR.

Indexed as

Anti-HIV AgentsAnti-Retroviral AgentsHIV-1HIV InfectionsTransients and MigrantsViral LoadAdultAfrica South of the SaharaDatabases, FactualFemaleFranceHumansMaleMiddle AgedAnti-HIV AgentsAnti-Retroviral Agentsgeographical originheterosexualHIVmigrantvirological rebound

Identifiers

PMID39497481
PMCPMC11786615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.